Display options
Cite
Anderson EM, Diorio C, Goodwin EC, et al. SARS-CoV-2 antibody responses in children with MIS-C and mild and severe COVID-19. medRxiv. 2020;doi: 10.1101/2020.08.17.20176552.
Anderson, E. M., Diorio, C., Goodwin, E. C., McNerney, K. O., Weirick, M. E., Gouma, S., Bolton, M. J., Arevalo, C. P., Chase, J., Hicks, P., Manzoni, T. B., Baxter, A. E., Andrea, K. P., Burudpakdee, C., Lee, J. H., Vella, L. A., Henrickson, S. E., Harris, R. M., Wherry, E. J., Bates, P., Bassiri, H., Behrens, E. M., Teachey, D. T., & Hensley, S. E. (2020). SARS-CoV-2 antibody responses in children with MIS-C and mild and severe COVID-19. medRxiv : the preprint server for health sciences, . https://doi.org/10.1101/2020.08.17.20176552
Anderson, Elizabeth M, et al. "SARS-CoV-2 antibody responses in children with MIS-C and mild and severe COVID-19." medRxiv : the preprint server for health sciences vol. (2020). doi: https://doi.org/10.1101/2020.08.17.20176552
Anderson EM, Diorio C, Goodwin EC, McNerney KO, Weirick ME, Gouma S, Bolton MJ, Arevalo CP, Chase J, Hicks P, Manzoni TB, Baxter AE, Andrea KP, Burudpakdee C, Lee JH, Vella LA, Henrickson SE, Harris RM, Wherry EJ, Bates P, Bassiri H, Behrens EM, Teachey DT, Hensley SE. SARS-CoV-2 antibody responses in children with MIS-C and mild and severe COVID-19. medRxiv. 2020 Aug 18; doi: 10.1101/2020.08.17.20176552. PMID: 32839782; PMCID: PMC7444298.
Copy Download .nbib Format: NLM
Share it on

medRxiv. 2020 Aug 18; doi: 10.1101/2020.08.17.20176552.

SARS-CoV-2 antibody responses in children with MIS-C and mild and severe COVID-19.

medRxiv : the preprint server for health sciences

Elizabeth M Anderson, Caroline Diorio, Eileen C Goodwin, Kevin O McNerney, Madison E Weirick, Sigrid Gouma, Marcus J Bolton, Claudia P Arevalo, Julie Chase, Philip Hicks, Tomaz B Manzoni, Amy E Baxter, Kurt P Andrea, Chakkapong Burudpakdee, Jessica H Lee, Laura A Vella, Sarah E Henrickson, Rebecca M Harris, E John Wherry, Paul Bates, Hamid Bassiri, Edward M Behrens, David T Teachey, Scott E Hensley

Affiliations

  1. Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA USA.
  2. These authors contributed equally to this work: Elizabeth M. Anderson and Caroline Diorio.
  3. Immune Dysregulation Frontier Program, Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
  4. Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
  5. Division of Rheumatology, Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
  6. School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA USA.
  7. Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  8. Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA, USA.
  9. Division of Infectious Diseases, Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
  10. Division of Allergy and Immunology, Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
  11. Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
  12. Penn Center for Research on Coronavirus and Other Emerging Pathogens, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

PMID: 32839782 PMCID: PMC7444298 DOI: 10.1101/2020.08.17.20176552

Abstract

SARS-CoV-2 antibody responses in children remain poorly characterized. Here, we show that pediatric patients with multisystem inflammatory syndrome in children (MIS-C) possess higher SARS-CoV-2 spike IgG titers compared to those with severe coronavirus disease 2019 (COVID-19), likely reflecting a longer time since onset of infection in MIS-C patients.

References

  1. Sci Immunol. 2020 Jul 29;5(49): - PubMed
  2. Lancet. 2020 May 23;395(10237):1607-1608 - PubMed
  3. Science. 2020 Sep 4;369(6508): - PubMed
  4. Lancet. 2020 Jun 6;395(10239):1771-1778 - PubMed
  5. J Pediatric Infect Dis Soc. 2020 Jul 13;9(3):393-398 - PubMed
  6. Nat Rev Rheumatol. 2020 Aug;16(8):413-414 - PubMed
  7. J Clin Invest. 2020 Nov 2;130(11):5967-5975 - PubMed
  8. N Engl J Med. 2020 Jul 23;383(4):334-346 - PubMed
  9. Acta Paediatr. 2020 Jun;109(6):1088-1095 - PubMed
  10. Nat Med. 2020 Jul;26(7):1033-1036 - PubMed
  11. MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):422-426 - PubMed
  12. N Engl J Med. 2020 Apr 2;382(14):1370-1371 - PubMed
  13. Sci Immunol. 2020 Jul 15;5(49): - PubMed
  14. N Engl J Med. 2020 Jul 23;383(4):347-358 - PubMed

Publication Types

Grant support